Hims eyes growth in its weight loss business, despite end of semaglutide shortage
Hims & Hers expects revenue from its weight loss business to soar in 2025, even though a recent FDA move could make it tougher for pharmacies and telehealth companies to offer certain compounded obesity drugs ...
